Aldosterone and Renin Evaluation for Primary Hyperaldosteronism
Screen for primary aldosteronism by simultaneously measuring plasma aldosterone concentration (PAC) and plasma renin (either plasma renin activity [PRA] or direct renin concentration [DRC]) to calculate the aldosterone-to-renin ratio (ARR), alongside serum potassium measurement. 1
Screening Test Components
The evaluation requires three simultaneous measurements:
- Plasma aldosterone concentration (PAC)
- Plasma renin - either PRA or DRC
- Serum potassium - not for screening itself, but essential for accurate interpretation of aldosterone levels
Medication Management Before Testing
The 2025 Endocrine Society guideline provides three practical approaches 1:
No-Withdrawal Strategy
- Test patients on their current antihypertensive regimen
- Interpret results considering each medication's known effects on renin and aldosterone
- Most pragmatic for initial case detection
Minimal-Withdrawal Strategy
- Adjust only the most interfering medications if feasible
- Balance between diagnostic accuracy and patient safety
Full-Withdrawal Strategy (Ideal)
- Provides optimal diagnostic precision
- Reserved for borderline cases or when initial results are equivocal
- Prioritizes accuracy over convenience 2
The contemporary approach emphasizes pragmatic, lower-barrier screening without mandatory medication withdrawal for initial testing, with adjustment reserved for inconclusive results or high clinical suspicion 2. This represents a significant shift from older rigid protocols that deterred screening uptake.
Defining a Positive Screen
A positive screen requires BOTH of the following conditions 1:
1. Suppressed Renin with Inappropriately Elevated Aldosterone
- PRA ≤1 ng/mL/h OR DRC ≤8.2 mU/L (suppressed renin is the diagnostic hallmark)
- AND aldosterone ≥10 ng/dL (≥277 pmol/L) by immunoassay OR ≥7.5 ng/dL (≥208 pmol/L) by LC-MS/MS
2. Elevated Aldosterone-to-Renin Ratio (ARR)
- Aldosterone [ng/dL] to PRA [ng/mL/h] ratio >20 when using immunoassay
- Aldosterone [pmol/L] to DRC [mU/L] ratio >70 when using immunoassay
- ARR thresholds are approximately 25% lower when aldosterone is measured by LC-MS/MS 1
Critical Technical Considerations
Assay-Specific Interpretation
The guideline explicitly acknowledges that cutoff values vary depending on local laboratory assays 1, 2. Recent research confirms that a modified ARR approach accounting for assay variability can improve sensitivity from 73.5% to 93.5% while maintaining 93% specificity 3.
The "Inappropriately Normal" Aldosterone Phenomenon
A critical pitfall: 67% of patients with confirmed PA had aldosterone <30 ng/dL, and 45% had levels <20 ng/dL 3. This means most PA patients do not have dramatically elevated aldosterone—the key is that aldosterone is inappropriately high relative to suppressed renin. Suppressed renin is the diagnostic cornerstone, not absolute aldosterone elevation.
Hypokalemia Management
If screening is negative but the patient has hypokalemia:
- Correct potassium to within the reference range
- Repeat screening after correction 1
Timing and Sample Collection
- Obtain morning samples, preferably between 0800-1000 hours 4
- Patient should be ambulatory
- Paired simultaneous measurement of aldosterone and renin is essential
When Confirmatory Testing is Needed
After a positive screen, the diagnostic pathway depends on clinical probability 2:
High Probability (bypass confirmatory testing in some cases)
- Marked biochemical abnormalities
- Young patient with clear unilateral adenoma on imaging
- Proceed directly to lateralization studies if surgical candidate
Intermediate Probability
- Confirmatory aldosterone suppression testing recommended
- Options include saline infusion, oral sodium loading, fludrocortisone suppression, or captopril challenge 5
Low Probability of Lateralizing Disease
- Proceed directly to medical therapy with mineralocorticoid receptor antagonists
The role of confirmatory testing is increasingly debated, with growing recognition that it may be bypassed in patients with clearly positive biochemical screening and high pretest probability, as it may not significantly improve diagnostic yield or affect clinical outcomes 2.
Common Pitfalls to Avoid
- Failing to recognize that most PA patients have "normal-range" aldosterone levels - focus on renin suppression 3
- Requiring medication withdrawal before initial screening - this creates unnecessary barriers 2
- Using ARR cutoffs without considering assay methodology - immunoassay vs. LC-MS/MS requires different thresholds 1, 6
- Screening without checking potassium - hypokalemia affects aldosterone interpretation 1
- Assuming a single negative screen excludes PA in hypokalemic patients - retest after potassium correction 1
The evidence strongly supports a streamlined, medication-tolerant approach to initial screening, with the understanding that equivocal results can be clarified through selective medication adjustment or confirmatory testing based on individual clinical context.